IRVINE, Calif.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS:SPPI - News), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration (FDA) on April 29, 2011, for the use of FUSILEV® (levoleucovorin) in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. This new, expanded indication supplements the original 2008 FDA approval of FUSILEV.
TTV : http://www.youtube.com/user/tritangotraderTV
TriTangoTraders.com
COmo es eso Jose, le aprobaron la droga pero durante la ruega cayo 13.13% y en el after ni se movio ?
ResponderEliminarLa droga fue aprobada a las 22 horas argentina con mercado cerrado , el lunes sabremos pero aparte da vuelta que TEVA otra farmaceutica podria adquirir a SPPI en estos dias .
ResponderEliminarsaludos buen fin de semana